Release Date: August 08, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: How can the ECO Synthesis platform be leveraged for drugs currently in clinical testing, and are there ongoing discussions with companies about this? A: Stephen Dilly, CEO, explained that the platform is applicable to drugs in development or on the market. Kevin Norrett, COO, added that companies are interested due to potential margin improvements. The platform can synthesize drugs using double-stranded RNA ligase, offering immediate cost savings, and is applicable for products in clinical trials.
Q: What are the remaining technical milestones for the ECO platform, and what does the first technical collaboration entail? A: Stephen Dilly, CEO, and Stefan Lutz, SVP of Research, noted that 2024 focuses on enzyme engineering and process development. Kevin Norrett, COO, mentioned that customers are interested in proof of concept for their constructs, and the ECO Innovation Lab will facilitate this. The collaboration involves comparing constructs to phosphoramidite chemistry counterparts.
Q: Can you discuss the demand for the optimization service launched recently and the customer preference between ordering kits or in-house optimization? A: Stephen Dilly, CEO, stated that the service allows customers to send substrates for rapid optimization, which has been well-received. This approach helps identify variants and conditions quickly, leading to a growing pipeline of potential candidates and increased customer engagement.
Q: What was the rationale for hiring Britton Jimenez as SVP of Commercial Operations, and what will be his focus? A: Stephen Dilly, CEO, explained that Britton Jimenez brings 20 years of CDMO experience, which is valuable for Codexis's growth. His focus will be on leveraging this expertise to drive the next phase of Codexis's development and commercial strategy.
Q: How is the current macro environment affecting funding in the pharma and biotech industry, and what are you hearing from customers? A: Kevin Norrett, COO, noted positive feedback regarding innovation budgets, with no significant pushback on funding. Companies are eager to invest in technology that can leapfrog current capabilities, indicating a willingness to fund projects in this space.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。